Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Jul 2018
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin (Primary)
- Indications Allotransplant rejection; Ataxia; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
- Focus Adverse reactions
- Sponsors Baxalta; Shire
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2018 Planned End Date changed from 31 Jan 2020 to 30 Jun 2020.
- 15 Feb 2018 Planned primary completion date changed from 31 Jan 2020 to 30 Jun 2020.